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 1 
The Double-Edged Sword of Medical Patents: How Monopolies on Healthcare Products 
Disparately Impact Certain American Populations 
Introduction 
The purpose of granting patents is to encourage innovation for the betterment of 
society. But do patents for healthcare products have a disparate impact on healthcare 
outcomes for certain racial, ethnic, and socio-economic groups or possibly public health in 
general?1 
The excessive costs associated with researching, developing, and patenting medical 
innovations lead inventors to charge consumers high prices to recoup their losses.2 While it 
is vital that inventors be able to repay the costs of creating and patenting new healthcare 
products, the necessity for profits forces consumers to bear the burden of the high costs of 
those products. Additionally, the high costs of research and development only incentivize 
inventors to research and invent solutions to problems that are in high demand, where 
profits will be higher.3 The necessity of access to healthcare products, especially 
pharmaceuticals, vaccines, and biotechnology, heightens the unfair burden of high costs.4 
The system of monopolies created by healthcare product patents has many impacts 
on the healthcare industry, inventors, and consumers. Because of the inherent competition 
among manufacturers and inventors, large research companies and manufacturers have 
created strategies to help each other, while discouraging smaller innovators and 
 
1 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global Policy, 
(Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730. 
2 Id. 
3 Id.  
4 Id. 
1
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eliminating competition.5 While the creation of patent law, which produces such 
competition, intends to encourage innovation among inventors, in reality patent law often 
encourages innovation only from industry giants.6 
Advances in the healthcare industry have created countless successful treatments 
and cures for many health issues, but these advancements are not as easily accessible to 
certain populations. It is well documented that people with low socio-economic status, as 
well as racial and ethnic minorities, have health inequity in the United States.7 This inequity 
stems, in part, from the high cost of physician visits and medication, as well as lack of 
access to preventative medicine and health insurance.8  
The deficiency of information and clarity surrounding the U.S. healthcare system 
creates further barriers to quality and affordable healthcare products and services.9 These 
systemic issues, the exceedingly high costs of many healthcare products and services, and 
the continual advancement of healthcare and technology allow for unequal access to 
healthcare for many populations and therefore creates problems for those populations, as 
well as the country as a whole. The issue of healthcare inequity, while a serious problem in 
 
5 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global Policy, 
(Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730. 
6 Id.  
7 Wayne J. Riley, Health Disparities: Gaps in Access, Quality and Affordability of Medical Care, Trans Am Clin 
Climatol Assoc. (2012), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540621/.  
8 David B. Nash, Health Inequities in America, Am Health Drug Benefits (2017), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620509/. 
9 Victor J. Dzau and Celynne A. Balatba, Health and Societal Implications of Medical and Technological 
Advances, Science Translational Medicine, (Oct. 28, 2017), 
https://stm.sciencemag.org/content/10/463/eaau4778. 
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the United States, is largely not a problem for many other developed countries but persists 
in many developing countries throughout the world.10 
There are a large number of proposed solutions and alternatives to the current 
patent system, but critics of the current system have yet to establish meaningful reforms 
that adequately incentivize innovation.11 Though many alternatives have been proposed, 
the flawed system that is currently in place is still more effective at serving the intent of 
patent policy than any proposed alternative.12 Until the proposed reforms address the key 
issues with the current system while also balancing the purpose of promoting innovation 
for the betterment of society, no reform can succeed. 
While many factors contribute to economic and healthcare inequity in the United 
States, the high prices of healthcare products and services created by medical patents are a 
significant contributor to this inequity. 
Background 
The history of the United States’ governance of patents emerges directly from the 
Constitution. “Congress shall have power . . . [t]o promote the progress of science and 
useful arts, by securing for limited times to authors and inventors the exclusive right to 
their respective writings and discoveries.”13 The inspiration for the constitutional language 
comes from England’s Statute of Monopolies, which regulated the Crown’s ability to grant 
 
10 Tara Leevy, Intellectual Property and Access to Medicine for the Poor, AMA Journal of Ethics (Dec. 2006), 
https://journalofethics.ama-assn.org/article/intellectual-property-and-access-medicine-poor/2006-12. 
11 Fran Quigley, Making Medicines Accessible: Alternatives to the Flawed Patent System, Health and Human 




13 U.S. Const. art. I, § 8. 
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limited monopolies.14 While the European patent regulation sought to gain revenue by 
regulating patents, the United States’ approach seeks to grant patents for the benefit of 
society.15 
In 1790, Congress codified patent regulations in the Patent Act.16 The Patent Act was 
the first American statute to denote innovation as property and granted patents for 
inventions that were “sufficiently useful and important,” to “promote the progress of useful 
Arts.”17 
Since its amendments in 1793, the Patent Act has remained largely unchanged.18 
The amendments sought to provide clearer designations for patent eligibility.19 To be 
granted a patent, the Patent Act requires that an invention be (1) novel, (2) useful, and (3) 
non-obvious.20 Recognizing the increased complexity of the healthcare industry and the 
potential impact on the American people, Congress sought to provide an extra level of 
protection and oversight for regulating healthcare products.21 In 1938, Congress passed the 
Federal Food, Drug, and Cosmetic Act, and in turn, created today’s Food and Drug 
Administration (FDA).22 The newly created FDA became responsible for regulating and 
 
14 A Brief History of Patent Law in the United States (May 7, 2014), https://ladas.com/education-center/a-
brief-history-of-the-patent-law-of-the-united-states-2/.  
15 Id.  
16 35 U.S.C. §§1-390. 
17 A Brief History of Patent Law in the United States (May 7, 2014), https://ladas.com/education-center/a-
brief-history-of-the-patent-law-of-the-united-states-2/.  
18 Victor J. Dzau and Celynne A. Balatba, Health and Societal Implications of Medical and Technological 
Advances, Science Translational Medicine, (Oct. 28, 2017), 
https://stm.sciencemag.org/content/10/463/eaau4778. 
19 Id.  
20 Id. §102. 
21 Food and Drug Administration (2020), https://www.fda.gov/medical-devices/overview-device-
regulation/history-medical-device-regulation-oversight-united-states (last visited Oct. 10, 2020). 
22 Id. 
4
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overseeing the creation and production of medical products.23 In 1962, the FDA enacted the 
Drug Amendments which required new safety tests, as well as a new requirement of 
substantial evidence of a drug’s safety.24 Congress then continued building and shaping 
patent law by instituting the 1976 Medical Device Amendments, which allows the FDA to 
evaluate the safety and effectiveness of medical devices.25 Today, the FDA requires 
extensive pre-clinical and clinical trials before any drugs, vaccines, or medical devices can 
enter the market.26 
Discussion 
Patents are essential for encouraging inventors and researchers to develop new and 
innovative creations for the betterment of society. Innovative ideas are especially critical in 
the healthcare field, partly because of their lifesaving potential. Modern medicine relies 
heavily on researchers who are committed to developing new vaccines, treatments, and 
medical technology in order to combat the ever-changing healthcare needs of patients.27 In 
many cases, these innovations can be the difference between life and death.  
However, an issue arises when the cost of developing and patenting these 
innovations allows the manufacturers to charge high prices for their inventions, resulting 
in costly medical products and services for consumers.28 While the intent behind patents is 
 
23 Food and Drug Administration (2020), https://www.fda.gov/medical-devices/overview-device-
regulation/history-medical-device-regulation-oversight-united-states (last visited Oct. 10, 2020). 
24 Id. 
25 Id. 
26 Id.  
27 Victor J. Dzau and Celynne A. Balatba, Health and Societal Implications of Medical and Technological 
Advances, Science Translational Medicine, (Oct. 28, 2017), 
https://stm.sciencemag.org/content/10/463/eaau4778.  
28 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
Policy, (Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730. 
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to incentivize researchers and inventors to find solutions to problems and encourage 
innovation, the intent was likely to allow for society to have easier access to these 
innovations, not to make them so expensive that some people struggle to afford them. This 
unequal access to healthcare products and services almost ensures healthcare inequity 
among racial and ethnic minorities and low socio-economic populations and can lead to 
disparate impacts for those populations. 
I. Unique challenges facing medical patents 
While the United States’ patent system is used to encourage innovation among 
inventors and artists to better society, when it comes to healthcare product patents, there 
are many considerations and unique challenges within the healthcare industry. One reason 
healthcare product patents are unique is their inherent impact on human life and well-
being.  
Because of the requirements of patentability, inventions with patents must serve 
novel and useful purposes and therefore lead to advances in society.29 The essential nature 
of healthcare products coupled with the high cost to develop a patented healthcare 
invention can often lead to circumstances where such inventions become unaffordable to 
many Americans.30  
Consumers sometimes do not have the luxury of choosing whether or not to 
purchase a product, since their health will suffer without the product. Consequently, these 
 
29 U.S. Patent and Trademark Office (2020), https://www.uspto.gov/patents-getting-started/general-
information-concerning-patents (last visited Sep. 20, 2020). 
30 Victor J. Dzau and Celynne A. Balatba, Health and Societal Implications of Medical and Technological 
Advances, Science Translational Medicine, (Oct. 28, 2017), 
https://stm.sciencemag.org/content/10/463/eaau4778.  
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consumers end up paying exorbitant prices for patented items, where their generic 
counterparts would be much less expensive.31 The high demand for healthcare products 
within the market often forces large manufacturers to choose between providing 
consumers affordable drugs, medical supplies, and other healthcare products or making 
higher profits from charging exceedingly high prices.32 
II. Monetary constraints of patent research & application process 
Considering the costs associated with creating a patentable invention, obtaining and 
maintaining a patent with the United States Patent and Trademark Office (USPTO), and 
maintaining approval from the FDA, it is clear how patent monopolies force manufactures 
to charge high prices.33,34 
A. Costs of research and innovation 
In 2017, the Pharmaceutical Research and Manufacturers of America (PhRMA) 
estimated that the average cost of research and development for a pharmaceutical 
company was $71.4 billion, which made up approximately 21.4% of those companies’ total 
sales.35 These figures are likely so high due to the high failure rate of pharmaceuticals.36 For 
example, between 2002 and 2012, the failure rate of drugs to treat Alzheimer’s Disease was 
 
31 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
Policy, (Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730.  
32 Wayne J. Riley, Health Disparities: Gaps in Access, Quality and Affordability of Medical Care, Trans Am Clin 
Climatol Assoc. (2012). 
33 U.S. Patent and Trademark Office (2020), https://www.uspto.gov/patents-getting-started/general-
information-concerning-patents (last visited Sep. 20, 2020). 
34 U.S. Food and Drug Administration (2020), https://www.fda.gov (last visited Sep. 18, 2020). 
35 Andrew Dunn, Drugmakers say R&D spending hit record in 2017, (August 15, 2018), 
https://www.biopharmadive.com/news/phrma-research-development-spending-industry-report/529943/. 
36 Pharmaceutical Technology (2020), https://www.pharmaceutical-
technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/ (last visited 
Oct. 10, 2020).  
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99.6%.37 While this statistic seems extreme, it is the reality for the majority of 
pharmaceutical researchers. Further, a successful approval rate of 0.4% does not mean that 
the approved drug is a cure or will even make a marked difference in the disease, it merely 
means that the drug gained approval.38 The most common reason drugs face such high 
failure rates is not because of extreme and dangerous side effects, it can be because after so 
much time and effort in development, the drugs just not effective enough to make an 
impact on patient health and cannot survive in the market.39 Further, when a large 
manufacturer determines that one of the drugs in development does not work, it can have 
detrimental implications for the company as a whole, such as drops in market shares.40 
Unlike pharmaceuticals, medical devices are much more diverse, some being very 
simple, such as a tongue depressor, and others very complex, such as a robotic surgery 
device. While these devices require the same rigorous research and development process 
as pharmaceuticals, the more complex devices often incur much higher operating costs.41 
Consider Magnetic Resonance Imaging (MRI): just like a simple medical device, an MRI 
machine requires rigorous time and money-intensive research and development, and 
requires continual maintenance, user training, and skilled operation, all of which create 
 
37 Pharmaceutical Technology (2020), https://www.pharmaceutical-
technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/ (last visited 
Oct. 10, 2020). 
38 Id. 
39 Id. 
40 Id.  
41 Marilyn J. Field and Thomas F. Boat, Medical Devices: Research and Development for Rare Diseases, The 
National Academies Press (2010), https://www.ncbi.nlm.nih.gov/books/NBK56199/.  
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increased expenses.42 Hospitals usually bear the costs of operation, training, and 
maintenance, which then passes to the consumer, likely at an even more inflated rate.43  
B. Costs of patent application and maintenance 
Due to the increasing complexity of the patent application process, the more 
complex the invention, the more costly obtaining a patent becomes. Inventors typically pay 
attorney fees that are ten to fifteen times the cost of the application itself, which can cost 
upward of $15,000, on top of fees to file the patent in other countries.44 In addition to those 
costs, patent holders must pay maintenance and other fees, resulting in an estimated total 
cost of between $160,000 and $330,000 for the life of the patent.45 
C. Impact of research and patent costs on consumers 
Once a patent product reaches the market, those costs associated with research and 
development, as well as patent expenses, pass directly to the consumer, which serves the 
purpose of patents and aligns with public policy.46 However, once those costs are recouped 
by the manufacturers, they continue to charge the same prices, resulting in large profits, to 
the detriment of the consumer.47 This overcharging is legal under current patent law in the 
 
42 Pro Imaging Services (2020), http://proimagingservices.com/wp-content/uploads/2014/10/How-Much-
does-it-Cost-to-Operate-an-MRI.pdf (last visited Oct. 24, 2020). 
43 Marilyn J. Field and Thomas F. Boat, Medical Devices: Research and Development for Rare Diseases, The 
National Academies Press (2010), https://www.ncbi.nlm.nih.gov/books/NBK56199/.  
44 Gene Quinn, The Cost of Obtaining a Patent in the US, (April 4, 2015), 
https://www.ipwatchdog.com/2015/04/04/the-cost-of-obtaining-a-patent-in-the-us/id=56485/. 
45 Joseph G. Hadzima, Jr., Importance of Patents: It Pays to Know Patent Rules, Boston Business Journal, (Dec. 7, 
2006), http://web.mit.edu/e-club/hadzima/the-importance-of-patents.html.  
46 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
Policy, (Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730. 
47 Id. 
9
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United States, but many critics hope to reform policies by opting for price ceilings to create 
more affordable healthcare products for consumers.48 
III. Economic effects of monopolies created by healthcare product patents 
The exorbitant costs of researching, developing, and patenting an invention causes 
companies to rely on the exclusive rights granted to them in order to charge such high 
prices for their product. A company can often manufacture a product at a high mark-up 
because of the relatively low cost of manufacturing.49 The company benefits from these 
high costs especially within the healthcare field, as oftentimes, such products are necessary 
for consumers’ health. The increasingly high demand for drugs, coupled with the vast 
inequality of access to healthcare in the United States, creates a platform for companies to 
charge extremely high prices and earn large profits.  
A. 20-year monopoly on all patented healthcare products 
A patent grants the patent holder the exclusive right to make, use, sell, offer to sell, 
keep the product, or import anything covered by the patent claims in any country where 
patent protection is granted. 50 This monopoly allows the patent holder to control the price 
at which he sells his invention, as well as excluding any competition within the market. 
Such impacts can have significant implications on healthcare product prices. 
 
48 Elle Mahdavi, Patents and the Pharmaceutical Industry, CA Review Management, 
https://cmr.berkeley.edu/2017/05/patents-and-
pharmaceuticals/#:~:text=Patents%20are%20a%20way%20to,would%20be%20accessible%20to%20all.  
49 Fran Quigley, Making Medicines Accessible: Alternatives to the Flawed Patent System, Health and Human 
Rights Journal, (Nov. 23, 2015), https://www.hhrjournal.org/2015/11/making-medicines-accessible-
alternatives-to-the-flawed-patent-system-2/.  
50 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
Policy, (Sept. 6, 2019), https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730.  
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 In addition to the exclusivity benefit that patent holders obtain, patents on 
pharmaceuticals face virtually no regulation on price once a healthcare product hits the 
market.51 This lack of restriction can lead to detrimental consequences for individuals who 
require medications to survive. For example, in 2015, Martin Shkreli was able to hike up 
the price of Daraprim, an AIDS medication, from $13.50 to $750 per pill.52 While this 
drastic price increase is completely legal, it could be regarded as immoral, and certainly 
leads to a disparate impact on healthcare access to vulnerable populations.53 This failure of 
regulation is a substantial issue with the patent system and continually affects the racial 
and ethnic minorities as well as low socio-economic populations.54 
 Another patent issue that arises in the healthcare industry is that while the intent 
behind patents is to encourage innovation, because of the necessity for exclusivity and the 
competition that it breeds, much of the research for innovations occurs in secret.55 While 
this makes sense for companies to beat out other companies in the race to develop and 
patent, it actually discourages open-source innovation, where researchers and inventors 
from several institutions and companies collaborate with each other, rather than 
competing with one another.56 Additionally, a large share of innovation is devoted to “me 
 
51 Elle Mahdavi, Patents and the Pharmaceutical Industry, CA Review Management, 
https://cmr.berkeley.edu/2017/05/patents-and-
pharmaceuticals/#:~:text=Patents%20are%20a%20way%20to,would%20be%20accessible%20to%20all.  
52 Id.  
53 Id.  
54 Id. 
55 Fran Quigley, Making Medicines Accessible: Alternatives to the Flawed Patent System, Health and Human 
Rights Journal, (Nov. 23, 2015), https://www.hhrjournal.org/2015/11/making-medicines-accessible-
alternatives-to-the-flawed-patent-system-2/.  
56 Id.  
11
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too” products, as in products that already have a high market value, rather than ones that 
offer new therapeutic benefits.57 
B. Effects of disease prevalence on market demand 
One of the most important factors when considering a patent is the potential 
demand for a product.58 While a monopoly on a medical invention allows a patent holder to 
have complete control over the market for that product, the patent holder can only make 
money if there is a demand for such a product within the market.59 In the healthcare field, 
there is a high demand for many medical devices, vaccines, and pharmaceuticals due to the 
potentially life-saving properties of the products.60 The high demand, however, deters 
innovators from researching health problems that are not as prevalent in society, which 
results in relatively few medical treatments or healthcare products.61 Because rare diseases 
affect only a small portion of the population, researchers are not as likely to recoup losses 
from costly research when the demand for the invention will likely have little earning 
potential.62 
If there is not a large market for a certain healthcare solution, such as a pill or 
vaccine for a rare disease, it likely will conjure much less attention from commercial 
inventors and researchers, as there will likely not be a large profit.63 In this regard, 
 
57 Fran Quigley, Making Medicines Accessible: Alternatives to the Flawed Patent System, Health and Human 





61 Amy Paturel, MS, MPH, Too Rare for Research? How to Handle an Orphan Disease, American Academy of 
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healthcare product patents only incentivize innovation if the product is in high demand or 
has the potential for a high market price.64  
To combat this conflict, Congress passed the Orphan Drug Act, as an amendment to 
the Federal Food, Drug, and Cosmetic Act in 1938.65 Congress sought to incentivize 
researchers to investigate and develop treatments to rare diseases by providing up to 50 
percent tax credits to developers, in addition to the benefits already obtained by patenting 
the inventions.66 In actuality, the rare diseases which inspired the Orphan Drug Act affected 
between 20 and 25 million people.67 
While there remains a need for research and development for rare disorder 
treatments, the incentives provided by the Orphan Drug Act saw over 200 approved 
products to treat orphan disorders by the year 2009, which provided treatment to eleven 
million patients.68 A potentially negative implication that results from the Orphan Drug Act 
is that many companies apply for Orphan Drug status once their original patent expires in 
an attempt to extend their patent for an extra seven years.69 Clearly, the Orphan Drug Act 
has its flaws, but the U.S. has yet to develop a solution without significant loopholes for 
 
64 Amy Paturel, MS, MPH, Too Rare for Research? How to Handle an Orphan Disease, American Academy of 
Neurology (May 2012) https://www.brainandlife.org/articles/too-rare-for-research-people-with-rare-
diseases-often-experience/. 
64 Id. 
65 Public Law 97 - 414. 
66 Id. 
67 John Swann, Ph.D. The Story Behind the Orphan Drug Act (Feb. 23, 2018), 
https://www.fda.gov/industry/orphan-products-development-events/story-behind-orphan-drug-act.  
68 Timothy Coté, M.D., M.P.H, Breakthrough Business Models: Drug Development for Rare and Neglected 
Diseases and Individualized Therapies, National Academies Press (2009), 
https://www.ncbi.nlm.nih.gov/books/NBK50974/#:~:text=During%20the%2025%2Dyear%20history,see%
20Figure%203%2D1).  
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treating rare disorders. One potential solution would be to enact a price ceiling on 
pharmaceuticals.70 A Kaiser Health News poll showed that 78 percent of the respondents 
supported the government creating a price ceiling on certain prescription drugs.71 
C. How monopolies are used as a weapon against small-scale inventors 
Large companies whose profits are dependent on the monopolies of healthcare 
products often employ cross-licensing of patents as a way to avoid interfering72 with other 
large companies’ innovation.73 While this allows large companies to have more freedom to 
innovate without worrying about infringing on existing patents, it can also result in the 
blocking of small-scale inventors from entering the market.74 Allowing small-scale 
inventors to participate in such innovation could lower costs to consumers and provide 
improved services that would disrupt the market for the larger companies.75 Excluding 
small inventors from entering the market benefits those large companies, but in turn, is a 
detriment to consumers and other small-scale inventors.76 
D. Competition once an original patent expires 
 




71 Id.  




74 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
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Once a patent expires, companies race to create new forms of essentially the same 
invention to obtain new patents and gain exclusivity in the market.77 However, once the 
original patent expires, those rivals have to compete against the generic versions, which 
often is accessible at a much cheaper price.78 
Often, when a company’s patent is set to expire, that company makes some minor 
changes to the drug, vaccine, or device to make it patent-eligible again, resulting in 
essentially an extension of the prior patent.79 This process is referred to as strategic 
patenting.80 Since the company already had the majority of the research and development 
done regarding the original product, a few tweaks to the existing product will take much 
less time and effort to make it patentable compared to other companies that are starting 
from scratch, thus creating an opportunity for the original patent-holder to have a 
perpetual patent on a product.81 This behavior weighs against public policy, as Congress’s 
intent when writing the Patent Act was to encourage innovation, and strategic patenting 
essentially devalues innovation by attempting to retain control of the market.82 
IV. Disparate impact of medical patents on healthcare in America 
The healthcare industry in the United States is a flawed but long-standing system. 
Even though all Americans routinely interact with the healthcare system, the interactions 
among different populations often lead to vastly different outcomes. There are many 
 
77 Denise L. Mayfield, JD, Medical Patents and How New Instruments or Medications Might Be Patented, MO. 
MED. (2016).  
78 Id. 
79 Helen Gubby, Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective, Global 
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personal factors that contribute to an individual’s overall healthcare experience, such as 
sex, geographic location, and socio-economic status, as well as external factors, like 
healthcare setting and broader environment.83  However, there is a consistently disparate 
impact among racial and ethnic minorities, as well as low socio-economic populations in 
the United States.84 This inequity, in part, stems from long-standing institutional racism as 
well as the politicization of healthcare as a privilege rather than a human right.85 
A. Racial, ethnic, and socio-economic inequality of healthcare access 
Racial and ethnic minorities, as well as low socio-economic groups, face increased 
healthcare inequities when compared to other populations in the United States.86 Because 
some Americans view healthcare as an economic issue, rather than a human rights issue, it 
is imperative that consumers treat shopping for healthcare products and services like 
shopping for other nonhealthcare products and services.87 To get high-value healthcare, 
consumers should compare the prices of different providers, products, and services to 
ensure that they are getting the best value for their money.88  
While cost-comparison makes sense generally for Americans, racial and ethnic 
minorities as well as low socio-economic populations have less access to information, 
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resources, and education to be able to adequately make these decisions.89 This lack of 
access is, in part, due to the vast complexity of the healthcare system and the heavy 
regulation of the industry.90 Further, while economic inequity has an impact on the 
healthcare of racial and ethnic minorities as well as low socio-economic populations, the 
overall healthcare industry has a substantial impact on the economy of the entire country.91      
In addition, while continual healthcare and technological advancement is a purpose 
of patent law and a benefit for society as a whole, such advancements can leave behind 
minorities and low-socioeconomic populations due to lack of education, information, and 
access to these advancements.92 
B. Patents disproportionately lessen access to healthcare/medicine based on racial, 
ethnic, and socio-economic variants 
Racial and ethnic minorities as well as low socio-economic populations already 
suffer from healthcare inequity due to several previously stated societal issues.93 The high 
prices of healthcare products and services resulting from patent monopolies only increase 
that inequity by creating unaffordable healthcare services, medications, and other 
healthcare products.94 
C. Healthcare as a political and economic issue, rather than a human rights issue 
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Healthcare is one of many issues on which Americans cannot agree. While some 
believe that access to healthcare is a human right that everyone is entitled to, others feel 
that it is an issue best left up to private companies and individuals to decide. While this 
issue is not black and white, healthcare as a political issue has become much more 
radicalized in recent years.95 While one might assume that divisions on healthcare beliefs 
exist across populations differing by race, sex, or socio-economic status, the starkest 
disagreements on healthcare are evident across political party lines.96 This political 
divisiveness allows Americans to debate healthcare just like other political issues.  
D. How lack of insurance heightens healthcare inequity 
The debate over healthcare reached a peak in 2010 when President Obama signed 
the Patient Protection and Affordable Care Act into law.97 The Affordable Care Act sought to 
provide insurance coverage to over 30 million uninsured Americans.98  
The uninsured in America tend to be disproportionately poor, young, and from 
racial or ethnic minority groups.99 Data from the American Community Survey between 
2008 and 2014 shows that prior to the enactment of the Affordable Care Act, 40.5 percent 
of Hispanic adults and 25.8 percent of Black adults in America were uninsured, as 
compared to 14.8 percent of white adults.100 There are many consequences that uninsured 
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people deal with, such as less access to preventive services, poorer health outcomes, higher 
disability rates, and lower earnings due to illness.101 A significant effect of being uninsured 
is the amount that uninsured individuals pay out of pocket for healthcare products and 
medications.102 
E. Impact of the U.S. as a high-income market 
Because a majority of healthcare products, especially pharmaceuticals, are typically 
inexpensive to manufacture, once a product is has a patent, it takes relatively little time to 
recoup losses from research, development, and patenting, and then companies can start to 
make large profits.103 As a result of patent monopolies, coupled with the essential nature of 
healthcare products and medicines, today’s pharmaceutical industry is one of the most 
profitable sectors in history.104 Because the U.S. is a high-income market, pharmaceutical 
companies can get away with charging exorbitant prices for drugs, and while many 
Americans struggle to afford these treatments, the high-income market dictates treatment 
rates.105 
V. Ripple effects outside the U.S. 
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The consequences facing indigent communities in the United States are also issues 
existing in many indigent countries, where people die of illness at high rates, even when 
effective treatments exist for those illnesses.106 
A. International patent regulation 
For a United States patent holder to obtain patent rights outside the United States, 
the patent holder must file an international patent application under the Patent 
Cooperation Treaty (PCT), which was established by the World Intellectual Property 
Organization.107 Upon approval, the patent holder will have a patent right with all countries 
that have ratified the PCT.108 The World Trade Organization (WTO) has established the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which seeks to 
establish a set of standard international rules regarding intellectual property.109 
Article 27 of the TRIPS Agreement allows governments to deny patents if its 
commercial exploitation could have a negative effect on human life or health.110 While the 
intent behind the TRIPS Agreement was to create a uniform system of regulation for 
intellectual property, it still had substantial issues, especially regarding developing 
countries and least developed countries (LCDs).111 Between 1995, when the TRIPS 
Agreement went into effect, and 2001, LCDs were exempt from TRIPS, but due to the lack of 
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production in LCDs, they often relied on importation from supplier countries, or they relied 
on compulsory patents.112 The importation of drugs often resulted in unaffordable drug 
prices and led to drug unavailability.113 Powerful interest also often pressured LCDs against 
engaging in compulsory patents.114 
Recognizing that they needed to do more to aid poor countries, especially with 
regard to HIV/AIDS, malaria, and tuberculosis epidemics, the WTO amended TRIPS in 2001 
with the Doha Declaration on Public Health (Doha).115  Doha’s goal was to allow member 
countries to alter their domestic patent laws so that compulsory license exports can help 
any country that might lack sufficient manufacturing ability.116 
 Still, the Doha amendment only permitted those supplier countries with a 
compulsory patent to sell the more affordable pharmaceuticals domestically, which did 
almost nothing to help LCDs who lack manufacturing capacity.117 In 2005, WTO finally 
amended the Doha Declaration on Public Health to allow countries with compulsory 
patents to alter their domestic patent law in order to provide other LCDs pharmaceuticals 
at a much lower cost.118 
B. US implications of international patent policy 
 
112 Tara Leevy, Intellectual Property and Access to Medicine for the Poor, AMA Journal of Ethics (Dec. 2006), 
https://journalofethics.ama-assn.org/article/intellectual-property-and-access-medicine-poor/2006-12.  
113 Id.  
114 Id. 






McGraw: The Double-Edged Sword of Medical Patents: How Monopolies on Heal
Published by University of Cincinnati College of Law Scholarship and Publications,
 22 
In early 2020, both of the major political parties in the United States proposed and 
supported the U.S.’s withdrawal from WTO, with both parties stating that the WTO no 
longer represents the interests of the United States.119 There is no way to know what 
lasting effects the pending U.S. withdrawal from the WTO might have on international 
intellectual property protections, especially with regard to medical and pharmaceutical 
patents. 
VI. Pharmaceutical industry impact on healthcare inequity 
The pharmaceutical industry has a reputation for charging high prices, to the 
detriment of consumers.120 Pharmaceutical companies recoup losses related to research 
and development from charging high prices for drugs. But because of the relatively low cost 
of manufacturing these drugs on a large scale, these companies are able to recoup losses 
fairly quickly and then make consistent profits by keeping drug costs high and 
overcharging consumers.121 This issue is a contributor to inadequate healthcare access in 
the U.S. among racial and ethnic minorities and low socio-economic populations.122 
The FDA can grant exclusivity to approved drugs in addition to the exclusivity that a 
patent grants, which means that the FDA will delay or prohibit approval of competitor 
drugs for a certain period of time.123 The policy behind exclusivity seeks to allow a balance 
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between pharmaceutical innovation and public access to drugs resulting from competition 
of generic drugs.124 While generic drugs promote public policy and force manufacturers to 
reduce drug costs to compete with any generic counterparts, one lasting issue is that 
companies use strategic patenting to extend their patents and create perpetual patents.125  
VII. How to reconcile the healthcare product patent issues 
The current U.S. patent system, although not perfect, does serve the Congressional 
purpose of encouraging innovation, but the innovation often comes from large 
manufacturers, to the detriment of small-scale inventors. Many ideas exist for how to better 
encourage innovation without many of the negative consequences of the current system, 
but none of the alternatives have been tested to see if they will result in better outcomes.126  
Until the day comes when a perfect patent system exists, our current patent system 
will have to suffice. Despite the inherent faults and consequences, the current system has 
unique benefits, such as forcing researchers to get creative with solutions so they can 
obtain their own patents.127 
A. Possible alternatives to the current patent system 
To be worthwhile, any legitimate alternative or reform to the current patent system 
must be able to provide comparable incentives to researchers and inventors. Designers of 
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an alternative solution would be required to better balance the need for incentives for 
companies to put in the time and money for research, development, and patenting, with the 
need for affordable access to healthcare products and services for racial and ethnic 
minorities and low socio-economic populations throughout the U.S.  
One potential change to the current patent system is implementation of a price 
ceiling for healthcare products.128 An issue that could arise, however, is that manufacturers 
might fear that they could not recoup their initial investments and incurred losses. A 
potential solution to this problem would be to allow companies to charge any price up until 
they earn enough money to recoup inherent losses and investments, and then institute a 
price ceiling to ensure more affordable and manageable prices for consumers. 
Another change that the USPTO could implement is to reduce the incidence of 
strategic patenting, often used by large manufacturers to perpetuate existing patents and 
maintain exclusivity within the market.129 Under current law, strategic patenting is 
completely legal, but it does nothing to benefit society and acts against the public 
interest.130 Interestingly, China has recently considered instituting a policy granting a one-
year exclusivity period for generic drugs to incentivize generic drug manufacturers.131 This 
would allow first-to-file generic drug patent applications to gain exclusivity in the market 
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for one year.132 While this could be a way to incentivize generic drug manufacturers, it is 
possible that the policy would encourage generic drug manufacturers to hike prices similar 
to their name-brand counterparts. 
Most proposed reforms focus on providing various “push” and “pull” incentives.133 
Push incentives focus on providing funding through grants and subsidies in the early stages 
of research and development.134 One of the most notable examples of this type of incentive 
is through the National Institutes of Health (NIH).135 The NIH provides approximately $30 
billion in funding annually for medical research and development.136 While government 
subsidies and philanthropy make up approximately 40 percent of all medical research 
funding, there are many other smaller push incentives out there for companies, from the 
private sector, academia, for-profit companies, and elsewhere.137 In addition to grants and 
other subsidies, another push incentive consists of tax credits for companies performing 
medical research and development.138  
While push incentives consist of providing funding and tax credits in the initial 
stages of research and development, pull incentives focus on the later stages.139 Pull 
incentives often take the form of monetary prizes or awards for the development of 
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treatments and other valuable healthcare products.140 While these push and pull incentives 
exist currently, they are mostly funded by private philanthropy.141 If pull incentives have 
hope to create meaningful reform to the current patent system, government investment in 
these prizes will be necessary to provide sufficient incentive to innovators.142 
Conclusion 
The patent system is an essential part of American medical and technological 
innovation, with its roots stemming from the text of the U.S. Constitution.143 While the 
patent system has evolved and improved regularly since its original codification in 1790, 
there is still much to be done to create a well-functioning patent system that not only 
promotes innovation for the betterment of society but also works for the American 
people.144 The various existing flaws within the current patent system, while perhaps not 
negatively affecting other industries, have the ability to have detrimental consequences for 
American consumers.  
One of the main issues with the current system is that the exorbitant costs 
associated with research, development, and patenting of healthcare products force many 
manufacturers to charge high prices to recoup losses.145 Further, even once those 
companies recoup their losses, they can continue to charge the same high prices to the 
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detriment of consumers.146 This price gouging likely happens in many other industries, but 
due to the essential nature of the healthcare field, many consumers do not have a choice 
and must pay for these healthcare products that affect the consumer’s health and 
wellbeing.147 While some American healthcare consumers can afford to pay the high prices 
of patented healthcare products, many cannot. For racial and ethnic minorities, as well as 
low socio-economic populations in the U.S., there exists a consistent inequity of healthcare 
access in general. The lack of affordability of patented healthcare products further 
exacerbates such disparities.148  
Monopolies created by patents are meant to provide exclusivity to the patent holder, 
helping to recoup initial investments for research and development, as well as to cover the 
costs of obtaining and maintaining the patent with the USPTO.149 While researchers need 
these incentives to make research and development worthwhile, the strategies employed 
by many companies actually discourage innovation by smaller inventors and leads to 
perpetual patents.150 Although patent laws are different for every country, one benefit 
many countries enjoy is being able to apply for patent rights in other countries. The WTO 
established the TRIPS Agreement, which created a standard set of rules for governing 
international patents.151 The WTO has reformed the TRIPS Agreement many times, in 
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hopes of improving the patent system and creating more equity of healthcare access for 
developing countries and LCDs.152  
The detrimental effects that the patent system has on vulnerable American 
populations is apparent in many developing countries that have little access to affordable 
healthcare products in addition to a lack of manufacturing capabilities. Interestingly, most 
other developed countries do not have many of the affordability problems that exist in the 
U.S. This issue, in part, is due to the healthcare system in the U.S., as opposed to the 
universal healthcare systems that exist in many other developed countries.153 There are 
many proposed changes surrounding the current patent system, ranging from price 
ceilings for healthcare products, reducing the prevalence of strategic patenting and 
perpetual patents, and providing further incentives to deter companies from charging 
excessive and unreasonable prices to the detriment of American consumers.154  
While there are many proposed alternatives to the current system, much more work 
is necessary to create meaningful reform. However, given the United States healthcare 
system’s dynamic nature, it is possible that the U.S. will begin to see reforms in many facets 
of the healthcare system, as the U.S. seeks to correct the inequity throughout the country. 
Because affordability of healthcare products and medicines is a highly contested issue 
among political parties, the topic is up for debate and hopefully this discussion will lead to 
reform and meaningful change for healthcare product patents.  
 
152 Tara Leevy, Intellectual Property and Access to Medicine for the Poor, AMA Journal of Ethics (Dec. 2006), 
https://journalofethics.ama-assn.org/article/intellectual-property-and-access-medicine-poor/2006-12. 
153 Id. 
154 Fran Quigley, Making Medicines Accessible: Alternatives to the Flawed Patent System, Health and Human 
Rights Journal, (Nov. 23, 2015), https://www.hhrjournal.org/2015/11/making-medicines-accessible-
alternatives-to-the-flawed-patent-system-2/. 
28
The University of Cincinnati Intellectual Property and Computer Law Journal, Vol. 5, Iss. 1 [], Art. 3
https://scholarship.law.uc.edu/ipclj/vol5/iss1/3
